“Almost everyone now wants dolutegravir, but we are trying to make this transition period gradual ... and people are very much looking forward to receiving TLD, the once-daily pill containing dolutegravir”
30 July 2019
Aibar is the director of Partnership Network, a national level organisation that works for access to treatment for people with HIV, hepatitis C and tuberculosis in Kyrgyzstan.
The Partnership Network works on a range of activities including negotiations with pharmaceutical companies for medicine availability and affordability. They also engage in updating clinical guidelines and promoting price reduction for a number of mechanisms.
With Kyrgyzstan slowly switching to a State drug provision system, dolutegravir was included in the Essential Medicines List in Kyrgyzstan, where Aibar’s organisation played an important role in the process. “Starting from September last year, people started to receive Dolutegravir. As of now, there are around 320 people on standalone Dolutegravir. Not yet on the TLD combination (tenofovir/lamivudine/dolutegravir) but they have Dolutegravir in their regimens. There were plans to have around 2,000 people on TLD by the end of the year.”
“Of course, people are happy that they’re being switched from efavirenz-based combinations to dolutegravir. Judging by the responses we have from people, they have considerably fewer side effects. Almost none at all. They are particularly happy about the fact that they’re not bound to the previous evening regimen.”
“Almost everyone now wants dolutegravir, but we are trying to make this transition period gradual. Some people still are stuck with the combination containing efavirenz, emtricitabine and tenofovir. But overall, people are happy that it’s a better regimen in terms of side effects. It’s much more convenient to take, and people are very much looking forward to receiving TLD, the once-daily pill containing dolutegravir.”
Speaking of some of the keys challenges, “one is the price of TLD that is currently being offered. We need to have two or three generics on the market in Kyrgyzstan to bring the price down further to a more competitive level. We are currently revising our treatment guidelines, and we’ll have them ready in September this year. We will include TLD as a preferred treatment regimen. By 2020, we’re expecting to have 80% of people on TLD.”
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.